ZFA-Logo

Who is the Top Dog in German Health Care System?

DOI: 10.3238/zfa.2016.0128-0130

Das BMG darf dem G-BA nicht vorschreiben, welche Arzneimittel von der Verordnungsfähigkeit ausgeschlossen werden

german translation / full article

Günther Egidi, Jörg Schaaber

Keywords: Glinides German Federal Joint Committee Reimbursement German Federal Ministry of Health

Germany´s Federal Ministry of Health is not Allowed to Enjoin on Federal Joint Committee Which Drugs should be Reimbursable

Summary: The Institute for Quality and Efficiency in Health Care (IQWIG) and the German Federal Joint Committee (G-BA) came to the conclusion in 2009 and 2010 respectively that the evidence for treatment with glinides is insufficient. Germany´s Federal Ministry of Health stopped in 2010 the exclusion of glinides from reimbursement by the G-BA. Five years after the Berlin higher social court rejected the ministries’ order –its intervention was declared as illegitimate. The competence of the organs of self-governance in German health care system was restored.


(State: 16.03.2016)

Latest Issue 10/2020

In Focus

  • Challenges of Acute Care
  • Is it Useful to Determine Hormone Levels in Healthy, Symptom-Free Postmenopausal Women?
  • Detecting Victims of Human Trafficking in Family Practice